Crigler-Najjar syndrome type 2

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:79235OMIM:606785E80.5
Who is this for?
Show terms as
3Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Crigler-Najjar syndrome type 2 (also called Arias syndrome) is a rare inherited liver disorder that affects how the body processes bilirubin. Bilirubin is a yellow substance made when red blood cells break down. Normally, the liver converts bilirubin into a form that can leave the body through bile. In Crigler-Najjar type 2, the liver enzyme responsible for this process — called UGT1A1 — works very poorly but not completely. This means bilirubin builds up in the blood, causing a yellow coloring of the skin and eyes called jaundice. Unlike the more severe type 1 form of this condition, people with Crigler-Najjar type 2 usually have moderately elevated bilirubin levels and a much better outlook. Most people live relatively normal lives, though they need ongoing monitoring. In some cases, especially during illness, fasting, or stress, bilirubin levels can rise high enough to cause serious problems, including brain damage (a condition called kernicterus or bilirubin encephalopathy). The main treatment is phototherapy — spending time under special blue lights that help break down bilirubin in the skin. A medication called phenobarbital can also help lower bilirubin levels in type 2 patients, which is an important difference from type 1. Liver transplant can be curative but is rarely needed for type 2. With proper management, most people with Crigler-Najjar type 2 do well long-term.

Also known as:

Key symptoms:

Yellow skin and eyes (jaundice) present from birth or early infancyElevated bilirubin levels in the bloodYellowing that may worsen during illness, fasting, or stressFatigue or low energy during bilirubin spikesIn severe or untreated cases: confusion, difficulty concentrating, or neurological symptoms from bilirubin affecting the brainPossible hearing problems if bilirubin levels have been very highNo other obvious liver disease symptoms in most casesGenerally normal growth and development with treatment

Clinical phenotype terms (3)— hover any for plain English
Neonatal hyperbilirubinemiaHP:0003265Unconjugated hyperbilirubinemiaHP:0008282
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

2 events
Nov 2024Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)

Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare — PHASE1

TrialRECRUITING
Aug 2024Perineal Massage in Pregnancy to Reduce the Levator Ani Coactivation

Azienda Sanitaria Universitaria Friuli Centrale — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Crigler-Najjar syndrome type 2.

View clinical trials →

No actively recruiting trials found for Crigler-Najjar syndrome type 2 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Crigler-Najjar syndrome type 2 community →

Specialists

3 foundView all specialists →
CF
Corey W Hunter, MD, FIPP
NEW YORK, NY
Specialist
PI on 1 active trial
WP
William E Whitehead, PhD
Specialist
PI on 1 active trial
DP
Denis V. Rebrikov, Dr., Professor,
Moscow
Specialist

Rare Disease Specialist

1 Crigler-Najjar syndrome type 2 publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Crigler-Najjar syndrome type 2.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Crigler-Najjar syndrome type 2Forum →

No community posts yet. Be the first to share your experience with Crigler-Najjar syndrome type 2.

Start the conversation →

Latest news about Crigler-Najjar syndrome type 2

Disease timeline:

New recruiting trial: Perineal Massage in Pregnancy to Reduce the Levator Ani Coactivation

A new clinical trial is recruiting patients for Crigler-Najjar syndrome type 2

New trial: Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)

Phase PHASE1 trial recruiting. GT-UGT1A1-AAV8-02

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What bilirubin level is safe for my child, and at what level should I seek emergency care?,Should my child take phenobarbital every day, and what are the side effects?,What triggers can raise bilirubin levels, and how do we manage them at home?,Does my child need phototherapy now, and how often might they need it in the future?,What is the long-term risk of brain damage, and how do we prevent it?,Should other family members be tested for this condition?,Are there any clinical trials or new treatments we should know about?

Common questions about Crigler-Najjar syndrome type 2

What is Crigler-Najjar syndrome type 2?

Crigler-Najjar syndrome type 2 (also called Arias syndrome) is a rare inherited liver disorder that affects how the body processes bilirubin. Bilirubin is a yellow substance made when red blood cells break down. Normally, the liver converts bilirubin into a form that can leave the body through bile. In Crigler-Najjar type 2, the liver enzyme responsible for this process — called UGT1A1 — works very poorly but not completely. This means bilirubin builds up in the blood, causing a yellow coloring of the skin and eyes called jaundice. Unlike the more severe type 1 form of this condition, people

How is Crigler-Najjar syndrome type 2 inherited?

Crigler-Najjar syndrome type 2 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Crigler-Najjar syndrome type 2 typically begin?

Typical onset of Crigler-Najjar syndrome type 2 is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Crigler-Najjar syndrome type 2?

3 specialists and care centers treating Crigler-Najjar syndrome type 2 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.